Preclinical study demonstrates sustained normoglycemia for twenty hours in diabetic mice, indicating a safe strategy for closed-loop insulin delivery.
Key Points
To engineer uniform, glucose-responsive microspheres using microfluidics for scalable and controlled closed-loop insulin delivery.
Fabricated insulin-loaded microspheres with uniform size and batch reproducibility via microfluidics using glucose oxidase (GOx) within a hybrid poly(lactic-co-glycolic acid) (PLGA) and acetalated dextran (Ac-dex) matrix.
Evaluated in vivo glucose regulation, hypoglycemic index, organ toxicity, and systemic inflammatory responses following subcutaneous administration in streptozotocin-induced diabetic mice.
Maintained normal blood glucose levels in streptozotocin-induced diabetic mice for at least 20 hours after single-depot administration.
Avoided treatment-induced organ toxicity and systemic inflammation while exhibiting a low hypoglycemic index.